Carl Ashley Morris - 27 Jan 2023 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role: Chief Scientific Officer
Signature: /s/ by David Tyrone Howton as attorney-in-fact for Carl Ashley Morris
Issuer symbol: SLDB
Transactions as of: 27 Jan 2023
Net transactions value: -$3,303
Form type: 4
Filing time: 31 Jan 2023, 20:18:53 UTC
Previous filing: 05 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SLDB	Common Stock	Options Exercise		+1,233	+6.5%		20,201	27 Jan 2023	Direct	F1, F2
transaction	SLDB	Common Stock	Sale	$3,303	-441	-2.2%	$7.49	19,760	27 Jan 2023	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SLDB	Restricted Stock Units	Options Exercise	$0	-1,233	-25%	$0.000000	3,700	27 Jan 2023	Common Stock	1,233		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Includes 490 shares of common stock and 1,462 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2022 and November 30, 2022, respectively.
F3	This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).
F4	On January 27, 2022 (the "Grant Date"), the reporting person was granted 4,933 restricted stock units, vesting in four equal installments on the anniversary of the grant date.